Letter to the editor for the article 'Efficacy and safety of neoadjuvant sintilimab in combination with FLOT chemotherapy in patients with HER2-negative locally advanced gastric or gastroesophageal junction adenocarcinoma: an investigator-initiated, single-arm, open-label, phase II study'

致编辑的信，关于文章“新辅助信迪利单抗联合 FLOT 化疗治疗 HER2 阴性局部晚期胃癌或胃食管交界处腺癌患者的疗效和安全性：一项研究者发起的单臂、开放标签 II 期研究”